Endonovo Therapeutics (ENDVD) Stock Price, News & Analysis

Company Overview

Endonovo Therapeutics, Inc. is a clinical‐stage medical technology company focused on the development and commercialization of novel electroceutical and photobiomodulation therapies. The company’s core research centers on the unique combination of non‐invasive pulsed electro-magnetic fields with targeted light therapy, aiming to accelerate tissue repair, modulate inflammatory responses and support more effective wound healing.

The company’s flagship platform delivers ultra‐short pulsed electrical stimulation in tandem with photonic activation to promote cellular regeneration and reduce healing times in chronic wound conditions, including diabetic foot ulcers and pressure wounds. Endonovo is actively conducting controlled clinical studies to evaluate safety and efficacy, and is pursuing regulatory clearances for its therapeutic devices in key markets.

Headquartered in Laguna Hills, California, Endonovo serves healthcare providers and research institutions primarily across North America. The company collaborates with leading academic and clinical partners to advance its technology pipeline, expand applications into new therapeutic areas and support its long‐term goal of offering non‐drug alternatives for inflammatory and degenerative conditions.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 11,850 shs
• Market Capitalization: $1.52 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:ENDVD
• CIK: N/A
• Web: endonovo.com
• Phone: (800) 489-4774
• Fax: N/A
• Employees: 147,000
• Year Founded: 2011

Profitability

• EPS (Trailing Twelve Months): ($10.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$400 thousand
• Net Margins: -6,075.54%
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -279.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $170 thousand
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.59) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 1,227,000
• Free Float: N/A
• Market Cap: $1.52 million
• Optionable: Not Optionable
• Beta: 1.98